Biofrontera

Biofrontera EBIT Margin

The EBIT Margin (Operating Margin) of Biofrontera (B8FK.DE) as of Nov 21, 2026 is -7.77 %. In the previous year, EBIT Margin (Operating Margin) was -13.03 % — a change of -40.34% (higher).

EBIT Margin

-7.77 %

YoY

-40.34%

Last updated:

EBIT Margin (Operating Margin) of Biofrontera is 2025 -7.77 % . EBIT Margin (Operating Margin) of Biofrontera was 2024 -13.03 % . It decreases by -40.34% higher compared to the previous year.

Biofrontera's operating (EBIT) margin stands at -7.8%, up from -122.8% several years earlier.

The Biofrontera EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2018
-87.54 EUR
Jan 1, 2019
-74.77 EUR
Jan 1, 2020
-18.49 EUR
Jan 1, 2021
-122.76 EUR
Jan 1, 2022
6.18 EUR
Jan 1, 2023
14.83 EUR
Jan 1, 2024
-13.03 EUR
Jan 1, 2025
-7.77 EUR
The Biofrontera EBIT Margin history
YEAREBIT MarginYoY
-7.77 %-40.34%
-13.03 %-187.85%
14.83 %+140.03%
6.18 %-105.03%
-122.76 %+564.04%
-18.49 %-75.28%
-74.77 %-14.59%
-87.54 %-24.45%
-115.88 %-39.69%
-192.14 %-22.29%
-247.25 %-19.66%
-307.76 %+13,329.21%
-2.29 %+121.35%
-1.04 %-87.80%
-8.49 %-43.69%
-15.07 %-6.79%
-16.17 %-33.36%
-24.27 %-43.90%
-43.27 %+43.67%
-30.11 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biofrontera Stock analysis

What does Biofrontera do? Biofrontera AG generates revenue by developing, selling, and distributing dermatological drugs and medical cosmetics for skin care, protection, and treatment. The company markets its portfolio which includes Ameluz for the photodynamic therapy of actinic keratoses, the PDT lamp BF-RhodoLED used in conjunction with Ameluz treatment, and Belixos, a herbal dermatological cream for conditions such as insect bites, burns, neurodermatitis, and psoriasis. These products address the needs of patients and healthcare providers seeking treatments for skin diseases and regenerative care of damaged skin. The firm also engages in the clinical development of drug candidates to expand its future revenue streams. This includes BF-derm1, a tablet containing an inhibitor that blocks histamine synthesis to prevent allergic reactions, and BF1, a selective serotonin receptor agent aimed at preventing migraines. Through its five wholly owned subsidiaries, notably B, Biofrontera AG supports these development and distribution activities from its headquarters in Leverkusen, Nordrhein-Westfalen. Biofrontera is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biofrontera stock

EBIT Margin (Operating Margin) of Biofrontera is -7.77 % in 2025.

EBIT Margin (Operating Margin) of Biofrontera changed from -13.03 % to -7.77 %, representing a -40.34% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) Biofrontera since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s Biofrontera with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Biofrontera

All Key Metrics — Biofrontera